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Abstract
Background & Aims: Drug	induced	liver	injury	(DILI)	is	challenging	because	of	the	lack	
of	biomarkers	to	predict	mortality.	Our	aim	was	to	describe	miRNA	changes	in	sera	of	
subjects	with	acute	idiosyncratic	DILI	and	determine	if	levels	of	miRNAs	were	associ-
ated	with	6	month	mortality.
Methods: Clinical	 data	 and	 sera	were	 collected	 from	 subjects	 enrolled	 in	 the	Drug	
Induced	Liver	 Injury	Network	prospective	study.	miRNAs	were	 isolated	from	serum	
obtained	from	78	subjects	within	2	weeks	of	acute	DILI	and	followed	up	for	6	months	
or	 longer.	miRNAs	were	compared	to	40	normal	controls	and	6	month	survivors	vs	
non-	survivors.
Results: The	mean	age	of	the	DILI	cohort	was	48	years,	and	55%	were	female.	Eleven	
(14.1%)	subjects	died,	10	within	6	months	of	DILI	onset,	5	(45%)	liver	related.	Lower	
levels	of	miRNAs-	122,	-	4463	and	-	4270	were	associated	with	death	within	6	months	
(P<.05).	None	of	 the	subjects	with	miRNA-	122	greater	 than	 the	median	value	died	
within	6	months	for	a	sensitivity	of	100%	and	specificity	of	57%.	In	subjects	with	a	
serum	albumin	<2.8	g/dL	and	miR-	122<7.89	RFU	the	sensitivity,	specificity,	positive	
and	negative	predictive	values	for	death	within	6	months	were	100%,	57%,	38%	and	
100%	respectively.
Conclusions: Serum	miRNA-	122	combined	with	albumin	accurately	identified	subjects	
who	 died	within	 6	months	 of	 drug	 induced	 liver	 injury.	 If	 confirmed	 prospectively,	
miRNA-	122	and	albumin	may	be	useful	in	identifying	patients	at	high	risk	for	mortality	
or	liver	transplantation.
K E Y W O R D S
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1  | INTRODUCTION
Drug	induced	liver	injury	(DILI)	is	an	increasingly	recognized	cause	of	
elevated	 liver	 tests.1	Elevations	 in	 serum	aminotransferases	and	 the	
potential	for	hepatotoxicity	are	among	the	most	common	reasons	that	
the	development	of	a	drug	is	abandoned.	Acute	liver	failure	from	drugs	
is	the	third	most	common	aetiology	for	liver	transplantation.2	For	most	
drugs,	with	the	notable	exception	of	acetaminophen,	DILI	from	drugs	
is	unpredictable	and	unrelated	to	dose	or	duration	of	therapy.3
There	are	several	challenges	when	diagnosing	and	managing	pa-
tients	with	 DILI.	 Diagnosing	 DILI	 can	 be	 difficult,	 and	 except	 for	 a	
positive	 rechallenge,	 there	 is	no	clear	gold	 standard	 for	establishing	
the	diagnosis.	Common	ways	to	make	a	diagnosis	DILI	are	by	expert	
Abbreviations:	DILI,	 drug	 induced	 liver	 injury;	DILIN,	Drug	 Induced	 Liver	 Injury	Network;	
miRNA,	micro	RNA;	RFU,	relative	fluorescent	unit;	RMA,	robust	multichip	averaging.
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opinion	or	RUCAM,	both	of	which	have	their	limitations.4,5	After	the	
diagnosis	 of	DILI	 is	 established	 the	 prognosis	 and	 resolution	of	 the	
injury	is	challenging	to	predict	with	up	to	18%–30%	of	patients	devel-
oping	chronic	injury.6	Hy	Zimmerman	was	perhaps	the	first	to	empha-
size	the	grave	prognostic	implication	of	hyperbilirubinaemia	in	acute	
hepatocellular	injury	because	of	drugs;	the	accuracy	of	what	has	been	
termed	“Hy’s	Law”,	namely	that	~10%	of	subjects	with	such	injury	will	
die	has	been	confirmed	repeatedly7–10	Thus,	by	the	time	jaundice	de-
velops	 the	 liver	 injury	 is	 fairly	 advanced,	 and	better	and	earlier	bio-
markers	that	may	predict	serious	injury	earlier	in	its	course	are	needed.
Changes	in	miRNAs	in	serum	have	been	shown	to	be	associated	
with	viral	hepatitis,	hepatobiliary	malignancies,	liver	fibrosis	and	injury	
from	acetaminophen.11–15	A	property	of	miRNAs	that	make	them	an	
attractive	biomarker	for	acute	 liver	 injury	 is	that	changes	 in	miRNAs	
may	occur	earlier	than	changes	seen	with	traditional	liver	tests.15 We 
have	previously	shown	that	relatively	lower	levels	of	four	cytokines	(IL-	
9,	IL-	17,	PDGF-	bb	and	RANTES,	among	27	tested)	and	serum	albumin	
are	highly	predictive	of	death	after	an	acute	DILI	event.16	The	aim	of	
the	current	study	was	to	define	miRNA	profiles	in	sera	of	subjects	with	
acute	DILI	 and	 to	determine	 if	 data	 from	 such	profiles	may	also	be	
useful	for	predicting	prognosis	in	drug	induced	liver	injury.
2  | METHODS
2.1 | Subjects studied
The	 study	 population	 has	 been	 previously	 described.10,16	 Subjects	
were	 enrolled	 in	 the	 prospective	 study	 of	 the	 Drug	 Induced	 Liver	
Injury	Network	(DILIN)	and	followed	up	for	a	minimum	of	6	months	
after	the	event.	Briefly,	serum	samples	and	detailed	clinical	data	were	
collected	 from	 subjects	 enrolled	 in	 the	DILIN	prospective	 study.5,10 
Written	informed	consent	was	obtained	from	subjects	and	the	study	
was	approved	by	the	Institutional	Review	Boards	of	all	participating	
clinical	sites.	The	full	names	of	the	ethics	committees	who	approved	
the	study	are	provided	in	the	supplementary	information.	Normal	con-
trols	 were	 recruited	 from	 the	 Indiana	 University-	Purdue	 University	
site.	Clinical	data	were	 reviewed	by	 the	DILIN	causality	 committee,	
which	adjudicated	cases	as	unlikely,	possible,	probable,	very	likely	or	
definite	and,	 in	cases	 involving	multiple	drugs,	assigned	each	drug	a	
score.	Types	of	 liver	 injury	 (hepatocellular,	mixed,	 cholestatic)	were	
classified	by	R	values.10
We	 studied	 78	 subjects	 with	 acute	 DILI	 enrolled	 between	
December	 2004	 and	 July	 2010	 who	 had	 serum	 samples	 obtained	
within	 2	weeks	 of	 clinical	 onset.	Whenever	 possible	 subjects	 were	
followed	up	 for	 6	months	or	 longer	 to	 determine	 if	 they	 recovered,	
died,	were	 transplanted,	or	developed	chronic	 injury.	Blood	samples	
were	collected	and	sent	to	a	central	DILIN	repository	for	processing	
and	storage	at	−80°C.	Sera	from	40	healthy	controls	(volunteer	blood	
donors)	with	no	known	history	of	liver	disease,	normal	levels	of	ALT,	
AST,	alkaline	phosphatase	and	total	serum	bilirubin	and	no	serologic	
evidence	of	active	hepatitis	A,	hepatitis	B,	hepatitis	C	or	HIV.
miRNAs	 were	 isolated	 from	 200	μL	 of	 serum	 using	 miRNeasy	
Mini	 Kit	 (Qiagen,	 Valencia,	 CA,	 USA).	 The	 samples	 were	 ligated	 to	
biotinylated	signal	molecules	using	FlastTag™	Biotin	HSR	RNA	labelling	
Kit	 (Genisphere	 LLC,	Hatfield,	 PA,	USA).	An	 enzyme	 linked	oligoab-
sorbant	 assay	 (ELOSA)	 QC	 assay	was	 performed	 to	 verify	 labelling	
prior	 to	array	hybridization.	Samples	were	hybridized	 to	GeneChip® 
3.0	miRNA	microarrays	(Affymetrix,	Santa	Clara,	CA,	USA).	This	chip	
contains	 1733	probes	 for	 human	mature	miRNAs	 and	1658	probes	
for	 human	 pre-	miRNAs.	 Probe	 level	 signal	 intensities,	 expressed	 as	
relative	fluorescent	 units	 (RFU)/200	μL,	were	 analysed	using	Partek	
Genomics	Suite	(Partek,	St	Louis,	MO,	USA).	Robust	multichip	averag-
ing	(RMA)	was	used	for	background	correction,	quantile	normalization,	
and	probeset	summarization	with	median	polish.	Mean	miRNA	inten-
sities	were	 compared	 using	 two-	way	ANOVA	 analysis	with	 suitable	
adjustment	for	multiple	comparisons	(Benjamini-	Hochberg	correction)	
limiting	false	discovery	rate	of	5%.
Descriptive	statistics,	 including	means	and	standard	deviations	or	
counts	and	percentages,	were	calculated.	For	interval	data,	Student’s	t-	
test	or	analysis	of	variance	(ANOVA)	was	used	to	compare	groups.	If	the	
data	were	not	normally	distributed,	the	Wilcoxon	rank	sum	test	or	the	
Kruskal–Wallis	test	was	employed.	For	nominal	data,	the	chi-	square	or	
Fisher’s	exact	test	was	used.	The	paired	t-	test	or	Wilcoxon	signed-	rank	
test	was	used	for	comparing	baseline	values	and	values	at	6	months.	
Spearman’s	correlations	were	calculated	to	assess	monotonic	relation-
ships	between	variables	measured	on	an	interval	scale.	Unless	other-
wise	specified,	a	two-	tailed	P-	value	of	<.05	was	considered	statistically	
significant.	SAS®	Enterprise	Guide®	5.1	was	used	for	all	analyses.
The	 following	 modelling	 process	 was	 used	 to	 select	 variables	
among	11	miRNAs	and	clinical	lab	test	results	for	prediction	of	early	
death	(within	6	month	of	DILI	onset).	Because	of	small	sample	size	(e.g.	
n=10	DILI	subjects	who	died	within	6	months	of	diagnosis)	and	the	rel-
atively	large	number	of	variables,	the	goal	was	to	find	a	stable	model17 
with	a	small	number	of	variables	that	is	highly	predictive	of	early	death.	
In	 the	 first	 step,	 univariate	 analyses	 were	 carried	 out	 to	 compare	
miRNA	values	between	those	died	within	6	months	of	DILI	onset	and	
those	who	survived	by	using	the	Wilcoxon	rank	sum	test.	Data	on	the	
miRNAs	that	were	significantly	associated	with	death	within	6	months	
were	then	examined	for	a	cut-	off	to	use	in	a	prediction	algorithm.	The	
Key points
•	 There	are	no	reliable	biomarkers	for	mortality	from	idio-
syncratic	drug	induced	liver	injury.
•	 In	subjects	with	evidence	of	acute	liver	injury	from	DILI	
relatively	lower	levels	of	serum	miRNAs	-122,	-4463	and	
-4270	were	associated	with	mortality.
•	 Levels	 of	miRNA	 122	 obtained	within	 2	weeks	 of	DILI	
onset	that	were	greater	than	the	median	of	8.31	RFU	had	
a	sensitivity	of	100%	for	predicting	survival.
•	 A	serum	albumin	<2.8	g/dL	and	miR-122	 less	than	7.89	
RFU	had	a	sensitivity	and	specificity	of	100%	and	57%,	
respectively,	 for	predicting	death	within	6	months	after	
acute	DILI.
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miRNA	with	the	best	predictive	results	(measured	by	overall	concor-
dance,	 sensitivity,	 specificity,	 positive	 predictive	value	 and	 negative	
predictive	value)	was	then	combined	with	serum	albumin	to	determine	
if	the	predictive	algorithm	could	be	improved.	In	a	previous	analysis	of	
this	dataset,	serum	albumin	 (≤2.8	g/dL),	a	critical	value	 in	the	Child-	
Turcotte-	Pugh	categorization	of	severity	of	liver	disease	was	identified	
as	a	strong	predictor	of	early	death.16
3  | RESULTS
The	 study	population	 consisted	of	78	 subjects	with	 acute	DILI	 and	
40	healthy	control	subjects	(Figure	1).	Selected	characteristics	of	the	
study	population	and	controls	are	shown	in	Table	1.	Six	month	follow-
	up	visits	occurred	in	37	DILI	subjects	among	whom	sera	was	obtained	
from	32	subjects.	Five	subjects	did	not	provide	serum	at	6	months.	
No	 subject	 underwent	 liver	 transplantation.	 The	 mean	 age	 of	 the	
DILI	cohort	was	48	years-	old	and	the	majority	were	female	(55%)	and	
Caucasian	(73%).	The	majority	of	subjects	(55%)	exhibited	hepatocel-
lular injury [R>5],	 followed	by	 cholestatic	 injury	 (22%)	 [R<2],	which	
was	similar	to	the	entire	DILIN	cohort	(Table	2).	Eleven	(14%)	subjects	
died,	10	within	6	months	of	DILI	onset.	Five	of	these	were	deemed	
by	the	DILIN	Committee	on	causes	of	death	to	have	died	because	of	
liver	disease,	whereas	six	from	a	non-	hepatic	cause.	One	subject	died	
315	days	after	DILI	onset	of	liver	related	cause	(Table	3).
3.1 | Acute drug induced liver injury and miRNA 
levels results
Among	 1733	miRNAs	 and	 1658	 precursor	miRNAs	 analysed,	 eight	
were	 statistically	 higher	 in	 acute	 DILI	 cases	 compared	 to	 controls	
(miR-	122,	 -	1246,	 -	4270,	 -	4433,	 -	4463,	 -	4484,	 -	4532,	 and	 pre-	
miR-	4767,	 P<.05)	 and	 three	 were	 significantly	 decreased	 in	 acute	
DILI	cases	compared	to	controls	 (miR-	455-	3p,	1281,	pre-	miR-	4274;	
Figure	2).	Among	the	DILI	cases	four	of	the	miRNA’s	were	also	signifi-
cantly	higher	at	baseline	compared	to	6-	month	follow-	up	(Figure	3).
3.2 | miRNA levels and death within 6 months of 
DILI onset
Three	 miRNAs	 were	 associated	 with	 death	 within	 6	months	 (miR-	
122,	 -	4463,	 pre-	miR-	4270,	P<.05)	 among	11	miRNAs	 analysed	 and	
five	were	associated	with	death	at	any	time	(miR-	122,	-	4463,	-	4270,	
F I G U R E  1  Flow	diagram	of	the	study	
subjects.	Sera	from	78	subjects	with	acute	
DILI	and	40	healthy	controls	were	analysed	
as	described	in	Methods	[Colour	figure	can	
be	viewed	at	wileyonlinelibrary.com]
78 subjects with acute DILI enrolled 2004-2012
11 subjects died within
6 months of DILI onset
32 subjects completed
6 months of follow-up
36 subjects did not complete 6
months of follow-up
Figure 1: Flow diagram of study populaon
Sera from 78 DILI subjects and 40 healthy controls were analyzed.
T A B L E  1  Selected	demographic,	clinical,	and	laboratory	features	
of	subjects	and	controls
DILI onset 
(n=78)
6 month 
follow- up 
(n=32)
Healthy 
controls 
(n=40)
Age,	mean	(SD)	years 48±17.9 51±14.2 49.2±13.1
Female	(%) 55 55 28
Self	reported	race	(%)
White 73 73 95
Black 10 10 5
Other/unknown 17 15 0
Body	mass	index	 
(kg/m2),mean±SD
27.1±6.5 30.5±6.9
Absolute	eosinophils/μL	
(mean±SD)
173±235
Liver	tests	(mean±SD)
ALT	(U/L) 1065±1382 55±131 17.5±5
AST	(U/L) 1003±1249 38±131 24±5
Alkaline	phosphatase	
(U/L)
336±465 89±33 63±14
Total	bilirubin	(mg/dL) 8.1±7.4 0.9±0.7 0.6±0.2
INR 1.8±1.2 1.1±0.4
MELD≤9a 10
10–19 34
20–29 17
30–39 5
≥40 1
aMELD	score	not	available	for	11	subjects.
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-	4433	and	pre-	miR-	4767,	P<.05)	vs	controls	(Figure	4).	Among	the	pa-
tients	with	DILI	who	survived	at	least	6	months	miR-	122	levels	were	
higher	compared	to	controls,	8.18	and	3.92	RFU/200	μL,	respectively,	
P=.001.	 Similarly,	 pre-	miR-	4270	 levels	were	 higher	 in	DILI	 subjects	
who	survived	at	least	6	months	compared	to	controls,	3.80	and	2.14,	
RFU/200 μL,	respectively,	P=.007,	as	were	miR-	4463	levels,	5.20	and	
2.92,	 respectively,	 P=.003	 (Figure	3).	 Mean	 levels	 of	 miRNA	 levels	
were	not	significantly	different	between	serum	samples	collected	on	
days	1–7	vs	8–14	after	onset	of	acute	injury.
3.3 | miR- 122, albumin and death from DILI
None	of	the	subjects	with	miR-	122	greater	than	the	median	value	for	
all	subjects	with	DILI	(8.31	RFU)	died	within	6	months	for	a	sensitivity	
of	100%,	specificity	of	57%,	positive	predictive	value	of	24%	and	nega-
tive	predictive	value	of	100%.	Serum	albumin	was	directly	associated	
with	6	month	survival,	and	none	of	the	subjects	with	a	baseline	serum	
albumin	 greater	 than	 2.8	g/dL	 died	within	 6	months.	 Because	 lower	
serum	albumin	and	miR122	were	associated	with	survival,	we	deter-
mined	which	values	provided	the	best	sensitivity	for	mortality.	A	value	
of	7.89	for	miR122	was	chosen	as	the	cut-	off	value	because	it	had	the	
best	discriminatory	value	for	prediction	of	outcome.	The	level	of	serum	
albumin	<2.8	g/dL,	a	value	that	is	used	in	the	Child-	Turcotte-	Pugh	scor-
ing	system	of	severity	of	liver	disease,	previously	had	been	shown	to	be	
a	useful	discriminatory	value.16	If,	at	baseline,	the	serum	albumin	was	
<2.8	g/dL	and	miR-	122	was	<7.89,	the	sensitivity,	specificity,	positive	
and	negative	predictive	values	were	100%,	81%,	38%,	and	100%	re-
spectively	(Table	4).	For	comparison,	a	MELD	score>17	had	a	sensitiv-
ity,	specificity,	positive	predictive	value,	negative	predictive	value	and	
accuracy	for	death	of	100%,	48%,	20%,	100%	and	54%	respectively.	
Other	MELD	scores	had	lower	overall	accuracies	for	predicting	death.
4  | DISCUSSION
The	major	 findings	 of	 this	 study	 are	 that,	 (i)	 Among	 3391	miRNAs	
and	pre-	miRNAs	tested,	only	11	were	significantly	different	between	
T A B L E  2  Selected	characteristics	and	outcomes	among	DILI	
subjects	studied	(n=78)
Pattern	of	injury	(%)
Hepatocellular 46	(59)
Cholestatic 17	(22)
Mixed 12	(15)
Unknown 3	(4)
Severity	of	injury	(%)
Mild 9	(11)
Moderate 38	(49)
Severe/fatal 20	(26)
Unknown 11	(14)
Liver	related	mortality	(%) 5	(45)
Chronic	DILI	(%) 4	(5)
T A B L E  3  Characteristics	of	subjects	who	died
Subject Implicated drug(s)
Days to 
death Cause of death
1 Oxacillin 102 Drug	overdose
2 Ciprofloxacin 27 Liver	related
3 XL-	999	(experimental	
tyrosine	kinase	
inhibitor	for	acute	
myeloid	leukaemia)
4 AML,	sepsis
4 Amlodipine 42 Subdural	
haemorrhage,	
sepsis
5 Vincristine,	
L-	asparaginase
136 Acute	lymphoblas-
tic	leukaemia
6 Nitrofurantoin 6 Liver	related
7 Ciprofloxacin,	niacin 6 Liver	related
8 Antithymocyte	globulin 6 Aplastic	anaemia
9 Carbamezepine 21 Thymoma
10 Amiodarone,	nafcillin 40 Liver	related
11 Phenytoin 315 Liver	related
F I G U R E  2  miRNA	levels	in	serum	
for	subjects	with	acute	DILI,	expressed	
as	fold-	difference	from	those	for	control	
subjects.	Y	axis	is	fold	change.	Only	the	11	
miRNAs	that	were	significantly	different	
after	adjustment	for	multiple	comparisons	
with	false	discovery	rate	limited	to	5%	
are	shown.	Values	for	8	were	significantly	
increased;	values	for	three	were	
significantly	decreased	[Colour	figure	can	
be	viewed	at	wileyonlinelibrary.com]
P = 1.09x10–11
P = 3.17x10–9
P = 3.7x10–5
P = 6.4x10–5
P = 1.2x10–4
P = 1.5x10–4
P = 2.0x10–4
P = 7.9x10–5
P = 2.5x10–7
P = 1.7x10–6–5
0
5
10
15
20
miRNA
Fold change in miRNA in DILI cases compared to controls
122 4532 4463 1246 4270 4484 4433 4467 455-3p 1281 4274
     |  761RUSSO et al.
subjects	with	acute	DILI	and	normal	controls,	with	eight	significantly	
higher	and	 three	significantly	 lower;	and	 (ii)	A	model	 that	uses	only	
the	relative	levels	of	miR-	122,	the	miRNA	most	significantly	elevated	
in	 acute	DILI,	 and	 level	 of	 serum	albumin	proved	 to	have	excellent	
prognostic	value	regarding	which	subjects	with	acute	DILI	will	live	or	
die	within	6	months	of	the	acute	event.
Identifying	biomarkers	 that	can	predict	 serious	acute	 liver	 injury	
from	drugs	may	have	practical	implications	for	clinical	practice	as	well	
F I G U R E  3  miRNA	Concentrations	differentially	distributed	among	DILI	onset	and	6	month	follow-	up.	Y	axis	is	fold	change.	Results	are	
shown	as	box	and	whisker	plots,	with	median	values	shown	as	central	horizontal	bars,	interquartile	ranges	[25–75%]	as	boxes,	and	arror	bars	
denoting	5–95‰	values.	*P<.05	by	Wilcoxon	rank	sum	test.	Controls	n=40,	Onset	N=78,	6	month	N=32
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as	drug	development.	Currently	biomarkers	or	prognostic	models	for	
acute	liver	failure	such	as	serum	alpha-	foetoprotein,	levels	of	clotting	
factors,	King’s	College	criteria,	serum	phosphorus,	APACHE	score	are	
not	specific	for	non-	acetaminophen	DILI	and	suffer	from	known	lim-
itations.18–20	Thus,	novel	biomarkers	are	needed	to	identify	individuals	
who	are	at	greatest	risk	for	mortality	or	for	chronic	hepatitis	after	an	
acute	drug	induced	liver	injury.
MicroRNA’s	 (miRNA)	 are	 small	 noncoding	 single	 stranded	 RNA	
molecules	that	modulate	gene	expression.	These	are	highly	conserved	
molecules	that	contain	approximately	21–25	nucleotides.	Thousands	of	
miRNAs	have	been	identified,	and	the	functions	of	most	of	them	remain	
largely	 unknown.	 However,	 investigators	 have	 reported	 associations	
between	aberrant	expression	of	miRNAs	and	disease	states.21–23	Micro-	
RNAs	are	found	not	only	in	tissue	but	also	in	serum,	plasma	and	periph-
eral	blood	mononuclear	cells	making	them	an	attractive	target	for	study.
In	the	current	study,	of	the	1733	miRNAS	analysed	only	11	were	
significantly	 different	 in	 patients	 compared	 to	 controls;	 expression	
of	 eight	miRNAS	were	 increased	 compared	 to	 controls	 and	 the	 ex-
pression	of	three	miRNAS	were	lower	compared	to	controls.	We	have	
previously	 shown	 that	 a	panel	 of	 four	 immune	analytes	 (IL-	9,	 IL-	17,	
PDGF-	bb	 and	 RANTES)	 and	 albumin	 has	 a	 high	 positive	 predictive	
value	of	death	within	6	months	of	DILI	onset.16	The	current	study	ex-
pands	upon	on	previous	work	and	demonstrates	that	miRNA	combined	
with	albumin	is	predictive	of	death	within	6	months	of	DILI	onset.
Among	 the	 increased	 miRNAs,	 miR-	122	 has	 been	 the	 most	 ex-
tensively	studied	and	more	than	70%	of	miRNA	Is	from	the	liver.24	Its	
level	 in	 serum	 is	 increased	 in	 hepatitis	 B,	 hepatitis	 C,	 non-	alcoholic	
fatty	 liver	 disease	 and	 decreased	 in	 hepatocellular	 carcinoma,	 fibro-
sis,	cirrhosis	and	metabolic	disorders.24	miR-	122	has	previously	been	
reported	to	be	 increased	 in	drug	 induced	 liver	 injury.25,26	Our	results	
indicate	that	increased	expression	miR-	122	is	also	associated	with	non-	
acetaminophen	acute	drug	induced	liver	injury.	In	a	study	of	53	subjects,	
circulating	miR-	122	was	significantly	higher	in	patients	with	acetamino-
phen	drug	induced	liver	compared	to	controls,	1265,	P<.001.21
miR-	122	 has	 been	 implicated	 in	 the	 regulation	 of	
7-	alpha-	hydroxlyase	 translation,	 an	 enzyme	 involved	 in	 cholesterol	
metabolism,	 the	 regulation	 of	 hepatocyte	 differentiation,	 and	 he-
patocyte	regeneration.15	It	has	also	been	shown	to	be	important	for	
replication	 of	 hepatitis	C	virus	 in	 hepatocytes,	 and	 the	 hepatitis	C	
virus	has	 recently	been	 identified	 to	be	 a	 “sponge”	 that	 “soaks	up”	
miR-	122	 in	 infected	 hepatocytes,	 preventing	 the	 action	 of	 Xrn2,	 a	
host	exonuclease	 that	otherwise	would	 lead	 to	breakdown	of	HCV	
RNA	within	the	cell.27–29	We	now	speculate	that	low	miR-	122	levels	
in	subjects	with	acute	DILI	could	be	associated	with	a	reduced	ability	
to	regenerate.
Although	the	role	of	miRNA-	122	has	been	extensively	studied,	the	
functions	 of	 the	 other	miRNAs	 associated	with	mortality	 from	DILI	
are	not	as	well	studied.	miR-	4270	has	been	associated	with	regulat-
ing	 early	 cellular	 differentiation	 and	 URG4/URGCP	 oncogene	 and	
renal cell carcinoma.30	miRNA-	4463	has	been	associated	with	insulin	
	resistance	and	polycystic	ovary	syndrome.31,32	A	study	of	miR-	1246	
demonstrated	 an	 association	 with	 increased	 hepatic	 differentiation	
in	mesenchymal	cells.33	Further	elucidation	of	 the	 function	of	 these	
miRNAs	is	needed	to	determine	if	there	is	biologic	plausibility	for	their	
association	with	mortality	from	DILI.
Despite	 analysing	 thousands	 of	 (pre)miRNAs,	we	 identified	 only	
three	that	were	associated	with	death.	There	was	a	consistent	asso-
ciation	among	miRNA-	122,	pre-	miRNA-	4270,	miR-	4463	 in	controls,	
DILI	subjects	who	survived,	and	DILI	subjects	who	died.	These	miRNA	
levels	were	 lower	 among	 the	 DILI	 subjects	 who	 died	 compared	 to	
those	who	survived,	yet	these	same	miRNAs	were	significantly	higher	
in	DILI	subjects	who	died	than	in	controls.	A	possible	explanation	for	
the	DILI	survivors	having	the	higher	miRNA	levels	is	that	the	survivors	
are	able	to	develop	a	compensatory	response	to	liver	injury	that	leads	
to	recovery.
We	 demonstrated	 that	 subjects	 with	 serum	 albumin	 <2.8	g/dL,	
with	 miRNA-	122<7.89	 accurately	 identified	 those	 at	 highest	 risk	
for	 death.	 In	 fact,	 our	model	 performed	better	 than	MELD	 score	 in	
predicting	 outcomes.	 In	 general,	 tests	 that	 accurately	 predict	 death	
from	acute	 liver	failure	are	 lacking	and	there	are	no	biomarkers	that	
F I G U R E  4  Values	for	miR-	122	among	those	who	survived	(n=68)	vs	died	(n=10)	within	6	months	of	DILI	onset.	Results	are	expressed	as	in	
Figure	3.	Y	axis	is	fold	change
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T A B L E  4  Outcome	of	subjects	with	serum	albumina	2.8	g/dL	and	
miRNA122<7.89
Death within 
6 months Alive
No.	of	predicted	to	die	within	6	months 8 13
No.	of	Predicted	to	live	>6	months 0 54
aOne	patient	did	not	have	a	serum	sample	for	albumin	and	was	excluded	
from	the	analysis.
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are	specific	for	mortality	from	drug	induced	liver	 injury.	Perhaps	not	
coincidentally,	serum	albumin	of	2.8	g/dL	is	also	the	cut	off	for	Child-	
Pugh-	Turcotte	C	classification	for	cirrhosis.	However,	we	assumed	that	
low	 albumin	was	 from	 hepatic	 synthetic	 dysfunction	 and	 not	 other	
causes	 of	 hypoalbuminaemia	 such	 as	 nephrotic	 syndrome.	 In	 other	
recent	work,	we	demonstrated	 that	 serum	albumin	 levels	 <2.8	g/dL	
were	useful	 in	combination	with	 levels	of	 four	cytokines	 for	predic-
tion	of	death	from	acute	DILI.16	The	addition	of	levels	of	miR-	122	to	
our	recent	model	of	cytokines	did	not	significantly	increase	accuracy	
any	further,	so,	at	this	time,	we	do	not	have	any	strong	rationale	for	
including	 levels	 of	 cytokines	 and	miRNAs	 into	 a	model	 for	 predict-
ing	 survival	vs	 death	 following	 acute	 severe	DILI.	Nevertheless,	 the	
model	of	miRNA-	122	and	albumin,	perhaps,	combined	with	values	of	
other	biomarkers,	such	as	immune	analytes,16	HMBG1,	for	example,17 
should	be	prospectively	validated	in	future	studies	of	mortality	from	
drug	induced	liver	injury.
This	study	has	several	strengths	including	the	carefully	character-
ized	78	subjects	with	DILI	of	known	acute	onset,	 the	 inclusion	of	a	
healthy	control	group	as	a	comparator,	and	development	of	a	simple	
model	using	albumin	and	miR-	122.	In	addition,	biomarkers	for	severe	
non-	acetaminophen	DILI	are	limited,	which	makes	our	study	unique.	
We	were	able	to	combine	an	easily	obtainable	liver	test,	albumin	with	
miRNA-	122	to	identify	a	promising	model	for	acute	death	from	DILI.	
Furthermore,	miRNA	was	obtained	from	the	blood,	an	easily	accessible	
tissue	compared	to	 liver	miRNA,	which	has	been	the	focus	of	many	
prior	studies.
Limitations	of	our	study	include	the	lack	of	a	validation	cohort,	a	
relatively	small	number	of	 fatal	cases,	and	the	 identification	of	miR-
NAs	with	significant	associations	with	death	but	as	of	yet	unknown	
function.	Whether	these	miRNAs	are	clinically	relevant	and	have	bi-
ologic	plausibility	are	unknown	and	warrant	further	study.	Before	our	
results	could	be	 recommended	for	clinical	practice,	 they	need	to	be	
prospectively	validated	in	other	cohorts	and	should	include	a	cohort	
that	includes	acute	liver	injury	from	non-	DILI	causes	as	a	comparison	
group.	Such	 further	 studies	are	 in	progress	 in	DILIN.	miRNA-	122	 in	
combination	with	 albumin	appears	 to	be	 the	most	promising	model	
for	further	study.
In	 conclusion,	 the	 serum	 level	 of	 miRNA-	122,	 especially	 when	
combined	 with	 serum	 albumin,	 is	 a	 promising	 early	 biomarker	 for	
identifying	individuals	at	highest	risk	for	mortality	within	6	months	of	
developing	severe	drug	induced	liver	 injury.	Perhaps,	miR-	122,	com-
bined	with	other	biomarkers,	such	as	selected	serum	cytokines,16 will 
increase	negative	and	positive	predictive	values	and	accuracy	of	pre-
diction.17,34	 In	addition,	study	of	these	markers	 in	acute	hepatitis	of	
other	aetiologies,	such	as	autoimmune,	ischaemic,	or	viral	hepatitis,	is	
important.	Currently	we	are	carrying	out	such	studies	to	validate	and	
extend	these	initial	findings.	The	focus	should	be	on	further	validation	
of	 this	 simple	model	 in	prospective	studies	because	of	 the	practical	
implications	it	may	have	in	clinical	practice.
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